Ablynx gets good results for inhaled drug

BRUSSELS (Reuters) - Belgian drug developer Ablynx has successfully completed early-stage tests on healthy volunteers for its inhaled treatment for RSV, a virus which is the most common cause of bronchiolitis in babies.

hallett auto body